CAS researchers confirm Gleevec’s first generation drug targets chronic myelogenous leukemia

Published on August 25, 2010 at 5:11 AM · No Comments

Today, leukemia patients who have struggled with cancer therapy resistance and intolerance will now have more options thanks to targeted drug therapy. Such new treatment options are due, in part, to a rapid increase in journal and patent publications following the discovery of Gleevec, as reported by Chemical Abstracts Service (CAS), the world's authority for chemical information.

Since President Clinton announced that the draft sequence of the human genome was completed in 2000, research about specific types of cancers grew exponentially. Fifty years of cancer and Chronic Myelogenous Leukemia (CML) drug treatments are examined in the CAS Chemistry Research Report: Human Genome Discoveries Spur Growth of Cancer Treatments. CAS researchers confirmed that Gleevec succeeded as a first-generation drug that targeted CML, as originally reported by Novartis and Oregon Health and Science researchers. Second- and third-generation CML-targeted drugs benefited from Gleevec's patent success and continued to propel the growth of CML research and patent publications.

Other important findings from the CAS report include:

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | العربية | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post